Codexis Launches Codex® HiTemp Reverse Transcriptase to

Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step quantitative reverse transcription PCR (RT-qPCR).

Related Keywords

John Nicols , Codexis Inc , Nasdaq , From Codexisdec , Hitemp Reverse Transcriptase , Reverse Transcriptase , Na , Iagnostic , Nzyme , Life Science , Ucleic Acid , Cars , Ars Cov 2 , Ranscription ,